Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I and Randomized Phase II Double Blinded Placebo Controlled Study of mFOLFOX6 +/- AMG 337 in the First Line Treatment of Patients With Her2/Neu Negative and High MET Expressing Advanced Gastric and Esophageal Adenocarcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT02344810
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:39:09.165656+00:00
Published At
2023-05-25T00:00:00+00:00
Record Updated At
2023-05-25
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Adenocarcinoma of the Esophagus", "Adenocarcinoma of the Gastroesophageal Junction", "Diffuse Adenocarcinoma of the Stomach", "Gastrointestinal Cancer", "Intestinal Adenocarcinoma of the Stomach", "Mixed Adenocarcinoma of the Stomach", "Stage IIIA Esophageal Cancer", "Stage IIIA Gastric Cancer", "Stage IIIB Esophageal Cancer", "Stage IIIB Gastric Cancer", "Stage IIIC Esophageal Cancer", "Stage IIIC Gastric Cancer", "Stage IV Esophageal Cancer", "Stage IV Gastric Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2023-05-25"
protocolSection.identificationModule.nctId
"NCT02344810"
protocolSection.identificationModule.officialTitle
"A Phase I and Randomized Phase II Double Blinded Placebo Controlled Study of mFOLFOX6 +/- AMG 337 in the First Line Treatment of Patients With Her2/Neu Negative and High MET Expressing Advanced Gastric and Esophageal Adenocarcinoma"
protocolSection.statusModule.overallStatus
"WITHDRAWN"
protocolSection.designModule.phases
["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Adenocarcinoma of the Esophagus (protocolSection.conditionsModule.conditions)
  • Adenocarcinoma of the Gastroesophageal Junction (protocolSection.conditionsModule.conditions)
  • Diffuse Adenocarcinoma of the Stomach (protocolSection.conditionsModule.conditions)
  • Gastrointestinal Cancer (protocolSection.conditionsModule.conditions)
  • Intestinal Adenocarcinoma of the Stomach (protocolSection.conditionsModule.conditions)
  • Mixed Adenocarcinoma of the Stomach (protocolSection.conditionsModule.conditions)
  • Stage IIIA Esophageal Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIA Gastric Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIB Esophageal Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIB Gastric Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIC Esophageal Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIC Gastric Cancer (protocolSection.conditionsModule.conditions)
  • Stage IV Esophageal Cancer (protocolSection.conditionsModule.conditions)
  • Stage IV Gastric Cancer (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.